Phaseline

Companies › Xenothera SAS

Xenothera SAS: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
XON7
glyco-humanized polyclonal antibody
–Phase 1Advanced Solid TumorDec 2026
LIS1
Glyco-humanized polyclonal antibody
–Phase 1Peripheral T Cells Lymphoma (PTCL)Dec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06154291XON7Phase 1Advanced Solid TumorOncologyDec 2026
NCT06495723LIS1Phase 1Peripheral T Cells Lymphoma (PTCL)OncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.